{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    20,
    25,
    26,
    34,
    41,
    45,
    47,
    48,
    49,
    50,
    52,
    54
  ],
  "modelUsed": "gemini-3-pro-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Contact List Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Title Page",
        "sectionTitle": "Title Page",
        "description": "Reference to Study Contact List for Medical Monitor information"
      },
      {
        "id": "ref_2",
        "name": "SoA Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA)",
        "description": "Reference to Table 1 Schedule of Activities"
      },
      {
        "id": "ref_3",
        "name": "Assessments Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8",
        "sectionTitle": "Study Assessments and Procedures",
        "description": "Reference to screening procedures detailed in Section 8"
      },
      {
        "id": "ref_4",
        "name": "COVID-19 Vaccine Risk Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.5",
        "sectionTitle": "COVID-19 Vaccine Risk Assessment",
        "description": "Reference to specific consideration for COVID-19 vaccine risks"
      },
      {
        "id": "ref_5",
        "name": "IB Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "N/A",
        "sectionTitle": "Investigator's Brochure",
        "description": "Reference to the Investigator's Brochure for safety results"
      },
      {
        "id": "ref_6",
        "name": "Dose Modification Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6",
        "sectionTitle": "Dose Modification",
        "description": "Reference to dose modification or discontinuation criteria"
      },
      {
        "id": "ref_7",
        "name": "Adaptive Features Table",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.1",
        "sectionTitle": "Overall Design",
        "description": "Reference to Table 4 for adaptive features and limits"
      },
      {
        "id": "ref_8",
        "name": "Dose Modification Table",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.1",
        "sectionTitle": "Overall Design",
        "description": "Reference to Table 7 for relevant Dose Modification criteria"
      },
      {
        "id": "ref_9",
        "name": "Exclusion Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2",
        "sectionTitle": "Exclusion Criteria",
        "description": "Reference regarding blood donation or blood loss"
      },
      {
        "id": "ref_10",
        "name": "Contraception Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Contraceptive Guidance and Collection of Pregnancy Information",
        "description": "Reference to appropriate contraceptive methods"
      },
      {
        "id": "ref_11",
        "name": "Inclusion Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1",
        "sectionTitle": "Inclusion Criteria",
        "description": "Reference to start times for contraceptives"
      },
      {
        "id": "ref_12",
        "name": "Pregnancy Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.6",
        "sectionTitle": "Pregnancy",
        "description": "Reference to pregnancy or planned pregnancy discontinuation criteria"
      },
      {
        "id": "ref_13",
        "name": "Lost to Follow-up Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.3",
        "sectionTitle": "Lost to Follow-up",
        "description": "Reference to definition of lost to follow-up"
      },
      {
        "id": "ref_14",
        "name": "AE Recording Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Adverse Events: Definitions and Procedures",
        "description": "Reference to procedures for recording, evaluating, follow-up, and reporting AEs and SAEs"
      },
      {
        "id": "ref_15",
        "name": "Genetics Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.7",
        "sectionTitle": "Genetics",
        "description": "Reference confirming sample will not be used for genetic testing"
      },
      {
        "id": "ref_16",
        "name": "Copper Measurement Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.1",
        "sectionTitle": "Copper and Molybdenum Balance Measurements",
        "description": "Reference for details of molybdenum measured in food, drinks, urine, and feces"
      },
      {
        "id": "ref_17",
        "name": "PD Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.6",
        "sectionTitle": "Pharmacodynamics",
        "description": "Reference for details of total copper and PUF-copper measurements"
      },
      {
        "id": "ref_18",
        "name": "Analysis Populations Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.3",
        "sectionTitle": "Populations for Analyses",
        "description": "Reference to Table 8 for population sets"
      },
      {
        "id": "ref_19",
        "name": "Lab Tests Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference to list of clinical laboratory tests to be performed"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 2001/20/EC... and 21 CFR part 312.30(b)",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Protocol Amendment Summary of Changes Table",
        "pageNumber": 3
      },
      {
        "id": "annot_2",
        "text": "Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; IB = Investigatorâ€™s Brochure; PK = pharmacokinetics; WD = Wilson disease.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 3: Potential Risks and Mitigation Strategy",
        "pageNumber": 21
      },
      {
        "id": "annot_3",
        "text": "Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of Activities.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 5: Participant Lifestyle Considerations",
        "pageNumber": 35
      },
      {
        "id": "annot_4",
        "text": "Abbreviations: ICF = informed consent form; PD = pharmacodynamic; PK = pharmacokinetic.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 8: Populations for Analysis",
        "pageNumber": 51
      },
      {
        "id": "annot_5",
        "text": "Note: total molybdenum and PUF molybdenum concentration-time profiles on Day 28 after the last 15 mg ALXN1840 dose will be extrapolated to Day 29 (0-24 hr) and subtracted from the observed Day 29 concentration-time profiles after the first 30 mg",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.4.4 Pharmacokinetic, Pharmacodynamic, and Biomarker Analyses",
        "pageNumber": 53
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "Amendment 3.1 (US)",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-03-18",
        "description": "Protocol Amendment 3.1 (US) clarifying study procedures across different US sites",
        "amendmentNumber": "3.1"
      },
      {
        "id": "ver_2",
        "versionNumber": "Original Protocol",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-12",
        "description": "Original Protocol",
        "amendmentNumber": "0"
      },
      {
        "id": "ver_3",
        "versionNumber": "Amendment 1",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-08-18",
        "description": "Amendment 1",
        "amendmentNumber": "1"
      },
      {
        "id": "ver_4",
        "versionNumber": "Amendment 2",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-03-19",
        "description": "Amendment 2",
        "amendmentNumber": "2"
      },
      {
        "id": "ver_5",
        "versionNumber": "Amendment 3",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-31",
        "description": "Amendment 3",
        "amendmentNumber": "3"
      }
    ],
    "summary": {
      "referenceCount": 19,
      "annotationCount": 5,
      "versionCount": 5
    }
  }
}